Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4 October 01, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005

OMB APPROVAL

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response...

0.5

Estimated average

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Sachdev Amit Issuer Symbol VERTEX PHARMACEUTICALS (Check all applicable) INC / MA [VRTX] 10% Owner (Last) (First) (Middle) 3. Date of Earliest Transaction Director X_ Officer (give title Other (specify (Month/Day/Year) below) C/O VERTEX 09/30/2014 SVP, Global Gov. Strategy **PHARMACEUTICALS** INCORPORATED, 50 NORTHERN **AVENUE** (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year)

BOSTON, MA 02210

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) 5. Amount of 7. Nature of Transactionr Disposed of (D) Ownership Indirect Security (Month/Day/Year) Execution Date, if Securities (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (I) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) V Code Amount (D) Price Common 09/30/2014 M 2,500 \$ 33.28 41,171 D Α Stock Common 09/30/2014 M 4,375 A \$ 39.05 45,546 D Stock Common 09/30/2014 M 10,500 A \$ 33.82 56,046 D Stock Common 09/30/2014 40,031 A D M \$ 38.8 96,077 Stock

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	09/30/2014	M	28,594	A	\$ 37.86	124,671	D	
Common Stock	09/30/2014	S <u>(1)</u>	11,354	D	\$ 111.33 (2) (3)	113,317	D	
Common Stock	09/30/2014	S(1)	34,753	D	\$ 112.22 (3) (4)	78,564	D	
Common Stock	09/30/2014	S(1)	22,646	D	\$ 113.13 (3) (5)	55,918	D	
Common Stock	09/30/2014	S <u>(1)</u>	17,247	D	\$ 113.91 (3) (6)	38,671	D	
Common Stock						882	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 33.28	09/30/2014		M	2,500	<u>(7)</u>	07/15/2019	Common Stock	2,500
Stock Option (right to buy)	\$ 39.05	09/30/2014		M	4,375	<u>(8)</u>	02/03/2020	Common Stock	4,375
Stock Option	\$ 33.82	09/30/2014		M	10,500	<u>(9)</u>	07/13/2020	Common Stock	10,500

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

(right to buy)								
Stock Option (right to buy)	\$ 38.8	09/30/2014	M	40,031	<u>(10)</u>	02/02/2021	Common Stock	40,031
Stock Option (right to buy)	\$ 37.86	09/30/2014	M	28,594	<u>(11)</u>	02/01/2022	Common Stock	28,594

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Sachdev Amit C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210

SVP, Global Gov. Strategy

Signatures

Kenneth L. Horton, Attorney-In-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$111.33 (range \$110.61 to \$111.60).
- (3) Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$112.22 (range \$111.62 to \$112.61).
- (5) Open market sales reported on this line occurred at a weighted average price of \$113.13 (range \$112.62 to \$113.60).
- (6) Open market sales reported on this line occurred at a weighted average price of \$113.91 (range \$113.62 to \$114.40).
- (7) Fully vested.
- (8) The option vests in 16 quarterly installments from 02/04/2010.
- (9) The option vests in 16 quarterly installments from 07/14/2010.
- (10) The option vests in 16 quarterly installments from 02/03/2011.
- (11) The option vests in 16 quarterly installments from 02/02/2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3